Proteins as Tolerogens to Induce Antigen Specific Immune Tolerance
Time: 11:10 am
day: Conference Day One
Details:
• Demonstrating TOL2’s potential as a disease-modifying treatment for myasthenia gravis, supported by preclinical efficacy, safety, and biomarker data NEW DATA
• Discussing critical features of antigen-specific tolerogens to achieve clinical efficacy
• Considerations for first in-human Phase I/IIa study of TOL2 in patients with generalized myasthenia gravis
